381 related articles for article (PubMed ID: 26461010)
61. The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma.
Kim TH; Kim JS; Suh YG; Cho J; Yang WI; Suh CO
Yonsei Med J; 2016 Jul; 57(4):846-54. PubMed ID: 27189276
[TBL] [Abstract][Full Text] [Related]
62. [Successful treatment with high-dose methotrexate/cytarabine regimen in a patient in SMILE regimen-resistant extranodal natural killer/T-cell lymphoma].
Saburi M; Itani K; Nagamatsu K; Miyazaki Y; Otsuka E; Urabe S; Saburi Y
Rinsho Ketsueki; 2014 Jan; 55(1):120-4. PubMed ID: 24492044
[TBL] [Abstract][Full Text] [Related]
63. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.
Lee KW; Yun T; Kim DW; Im SA; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
Leuk Lymphoma; 2006 Jul; 47(7):1274-82. PubMed ID: 16923557
[TBL] [Abstract][Full Text] [Related]
64. Management of extranodal natural killer/t-cell lymphoma, nasal type.
Chaudhary RK; Bhatt VR; Vose JM
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):245-52. PubMed ID: 25659751
[TBL] [Abstract][Full Text] [Related]
65. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.
Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R
Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870
[TBL] [Abstract][Full Text] [Related]
66. Current and future management of NK/T-cell lymphoma based on clinical trials.
Yamaguchi M
Int J Hematol; 2012 Nov; 96(5):562-71. PubMed ID: 23073619
[TBL] [Abstract][Full Text] [Related]
67. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
[TBL] [Abstract][Full Text] [Related]
68. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.
Kwong YL; Kim WS; Lim ST; Kim SJ; Tang T; Tse E; Leung AY; Chim CS
Blood; 2012 Oct; 120(15):2973-80. PubMed ID: 22919026
[TBL] [Abstract][Full Text] [Related]
69. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
Liang R; Gao GX; Chen JP; Wang JS; Wang XM; Zeng Y; Bai QX; Zhang T; Yang L; Dong BX; Gu HT; Shu MM; Hao CX; Wang JH; Zhang N; Chen XQ
Hematol Oncol; 2017 Dec; 35(4):619-629. PubMed ID: 27723108
[TBL] [Abstract][Full Text] [Related]
70. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma.
Wang H; Li YX; Wang WH; Jin J; Dai JR; Wang SL; Liu YP; Song YW; Wang ZY; Liu QF; Fang H; Qi SN; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1115-21. PubMed ID: 21514070
[TBL] [Abstract][Full Text] [Related]
71. A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiation in cervical cancer.
Choi CH; Lee YY; Kim MK; Kim TJ; Lee JW; Nam HR; Huh SJ; Lee JH; Bae DS; Kim BG
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1252-7. PubMed ID: 21075554
[TBL] [Abstract][Full Text] [Related]
72. Prophylactic cervical lymph node irradiation provides no benefit for patients of stage IE extranodal natural killer/T cell lymphoma, nasal type.
Wang L; Xia ZJ; Lu Y; Zhang YJ
Med Oncol; 2015 Jan; 32(1):320. PubMed ID: 25429828
[TBL] [Abstract][Full Text] [Related]
73. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M
Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152
[TBL] [Abstract][Full Text] [Related]
74. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
75. A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group.
Kim TM; Kim DW; Kang YK; Chung J; Song HS; Kim HJ; Kim BS; Lee JS; Kim H; Yang SH; Yuh YJ; Bae SH; Hyun MS; Jeon YK; Kim CW; Heo DS
Oncologist; 2014 Nov; 19(11):1129-30. PubMed ID: 25280488
[TBL] [Abstract][Full Text] [Related]
76. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma.
Yoo C; Yoon DH; Jo JC; Yoon S; Kim S; Lee BJ; Huh J; Lee SW; Suh C
Ann Hematol; 2014 Jun; 93(6):995-1000. PubMed ID: 24441948
[TBL] [Abstract][Full Text] [Related]
77. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
78. A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy.
Cao J; Lan S; Shen L; Si H; Zhang N; Li H; Guo R
Oncotarget; 2017 Mar; 8(12):20362-20370. PubMed ID: 27901491
[TBL] [Abstract][Full Text] [Related]
79. Delayed Diagnosis of a Nasal Type Lymphoma Misdiagnosed as Persistent Sinusitis.
Celentano A; Mascolo M; Cirillo N; De Rosa G; Mignogna MD
J Adolesc Young Adult Oncol; 2017 Jun; 6(2):381-384. PubMed ID: 28061034
[TBL] [Abstract][Full Text] [Related]
80. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
